Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | +0.19% | +4.13% | +4.13% |
Feb. 28 | Transcript : ImmuCell Corporation, Q4 2023 Earnings Call, Feb 28, 2024 | |
Feb. 27 | ImmuCell Corporation Enters into an Allonge to and Amendment of Line of Credit with Gorham Savings Bank | CI |
Financials (USD)
Sales 2021 | 19.24M | Sales 2022 | 18.57M | Capitalization | 47.26M |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | -2M | EV / Sales 2021 | 3.22 x |
Net Debt 2021 | 89.03K | Net Debt 2022 | 6.69M | EV / Sales 2022 | 2.91 x |
P/E ratio 2021 |
-776
x | P/E ratio 2022 |
-18.9
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 71.13% |
Latest transcript on ImmuCell Corporation
1 day | +0.19% | ||
1 week | +4.13% | ||
Current month | +0.38% | ||
1 month | +3.11% | ||
3 months | +12.53% | ||
6 months | -0.93% | ||
Current year | +4.13% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Brigham
CEO | Chief Executive Officer | 63 | 89-08-31 |
Director/Board Member | 48 | 09-12-31 | |
Corporate Officer/Principal | 68 | 16-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brigham
CEO | Chief Executive Officer | 63 | 89-08-31 |
Chairman | 67 | 06-12-20 | |
Director/Board Member | 48 | 09-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.3 | +0.19% | 14 713 |
24-03-27 | 5.29 | +2.52% | 13,074 |
24-03-26 | 5.16 | -1.71% | 2,120 |
24-03-25 | 5.25 | +0.38% | 11,358 |
24-03-22 | 5.23 | +2.75% | 3,571 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+4.13% | 41M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |